Argos Therapeutics, Inc. (NASDAQ:ARGS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday.
According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “
Separately, FBR & Co dropped their price target on shares of Argos Therapeutics from $2.00 to $1.20 and set a “mkt perform” rating on the stock in a research report on Wednesday, April 19th. One analyst has rated the stock with a sell rating and three have assigned a hold rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $3.23.
Argos Therapeutics (NASDAQ ARGS) traded up 1.6170% on Monday, reaching $0.2388. 1,230,130 shares of the company were exchanged. The firm’s market capitalization is $9.87 million. The stock has a 50 day moving average of $0.31 and a 200 day moving average of $1.13. Argos Therapeutics has a 12-month low of $0.23 and a 12-month high of $5.68.
Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. Argos Therapeutics had a negative net margin of 12,391.15% and a negative return on equity of 1,442.99%. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.10 million. Equities analysts anticipate that Argos Therapeutics will post ($1.14) EPS for the current year.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
